Skip to main content
Equibles

OBX · Obsidian Therapeutics, Inc.

Track OBX — free

Use OBX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OBX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$13.25 +1.31 (+10.97%) At close · Oct 20
Rebalance outlook locked
Market Cap
$737.57M
Shares
61.77M
Volume · Oct 20 410.95K Avg daily vol (3M) 381.97K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$13.25 Open$11.97 Day$11.57–13.47 Available close range$11.77–35.00 Avg vol 30d601K Short int885K · 1.4% float · 1.0d Short vol74% Last earningsAug 3, 2026 DataJul 2026–Oct 2026 Filing10-Q · Aug 14

The closing range uses available history since Jul 28, 2026; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Aug 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$94.22M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-12.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$16.46M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+56.4%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
1.4%
Latest settlement · 1.0 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Limited Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −20%
below
RSI (14) 47
neutral
MACD trend Positive
52-week position 6%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.43% of float · ▲ +249.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Squeeze score 50
elevated · 0–100
Fundamentals
Poor
EPS growth −12%
Y/Y
Free cash flow $-90.5M
Quant / Vol
risk profile
Very High
Volatility 217%
annualized · 1-yr
Max drawdown −66%
past year
ATR 11.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−20% Bearish
RSI (14)
47 Neutral
MACD trend
Positive Bullish
52-week position
6% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.43% of float · ▲ +249.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its available closing range
Range low $12 Now $13 · 6% Range high $35
vs 50-day avg -20%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
cash, cash equivalents and marketable securities 58.8M As of March 31, 2026 —
Employees engaged in business development, finance, information technology, and general manageme 17 As of March 31, 2026 —
Employees engaged in research and development 53 As of March 31, 2026 —
Employees with M.D. or Ph.D. degrees 26 As of March 31, 2026 —
Full-time employees 71 As of March 31, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
OBX
Obsidian Therapeutics, Inc.
this stock
$737.57M — — — 1.4%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +13.5% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +4.6% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $66.34B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest Rising
Shares short
884.5K
Days to cover
1.0d
Change
+631.4K sh
View
Short Volume
Short vol %
74%
As of
Oct 20, 2026
Short Total
View
Fails to Deliver
FTD shares
5.0K
Value
$73.0K
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
24.2%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-100.6M
EPS diluted
$-7.22
View
Filings
SEC Filings
Latest
8-K/A
Filed
Aug 14, 2026
This year
3
View
Earnings & Events
Webcasts
Last webcast
Aug 3, 2026
View

Performance

5D 20D 120D MTD YTD
OBX +10.5% -22.1% — -3.5% —
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY +11.7% -21.5% — -4.3% —
Key facts CIK 2130606 CUSIP 67448A106 Visit website Investor relations